Multiple Myeloma
From the Journals
Myeloma risk score has treatment-planning potential
The score could be used to modify doses prior to treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
Selinexor hits FDA stumbling block
The Oncologic Drugs Advisory Committee expressed concern about the high rate of serious adverse events with the drug being developed to treat...
Conference Coverage
MRD negativity linked to survival in MM after auto-HCT
HOUSTON – MRD-negative status was prognostic for improved progression-free survival at all time points measured after transplant.
From the Journals
Similar results for once- or twice-weekly carfilzomib in MM
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
News
FDA approves daratumumab split-dosing regimen in MM
The split-dose regimen resulted in a similar rate of infusion site reactions.
From the Journals
Trial supports less aggressive myeloma treatment
A less intensive transplant and maintenance strategy proved equally effective as more aggressive approaches in patients with multiple myeloma.
From the Journals
AML, myeloma risk higher for breast cancer survivors
Risk for both myeloid and lymphoid neoplasms was higher among breast cancer survivors than in the general population.
From the Journals
With RRMM and renal impairment, carfilzomib improves survival
In a subgroup analysis from ENDEAVOR, progression-free survival was more than doubled, compared with bortezomib.
Conference Coverage
Next-generation anti-BCMA CAR T shows promise for RRMM
SAN DIEGO – CAR T cells have been detectable up to 9 months after infusion.
News
Group proposes new grading systems for CRS, neurotoxicity
A group of experts has proposed new consensus definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity related to...